The Ocugen Inc (NASDAQ:OCGN) stock was in focus among many investors after the company stated that it is going to present the preclinical data with regards to its product OCU 200. The product is meant for the treatment of ocular neovascular diseases.
The data is going to be presented by Ocugen at the 2021 annual meeting of the Association for Research in Vision and Ophthalmology. However, the news did not seem to impress investors much and the stock continued to slide to take its decline over the past week to 40%.
While the stock may have tanked it is also necessary to point out that the product is comparable to Aflibercept when it comes to the reduction to neovascularisation and retina damage control. However, it should be noted that these findings were made in an animal study. At this point in time, it might be a good move for investors to track the stock and see if there’s a rebound.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life